Stryker shares tumble despite strong Q2 results and raised guidance
Fred Lampropoulos, President and CEO of Merit Medical Systems Inc. (NASDAQ:MMSI), a $5.5 billion market cap medical device company with a GREAT financial health score according to InvestingPro, reported a sale of 400 shares of the company’s common stock on June 10, 2025. The shares were sold at a price of $95.61 each, totaling $38,244. Following this transaction, Lampropoulos holds 1,045,628 shares directly.
This transaction is part of the non-derivative securities activities reported by Lampropoulos. Additional holdings include shares owned indirectly through a spouse and a 401(k) plan. These indirect holdings consist of 7,734 shares by a spouse and 97,892 shares through the 401(k) plan, according to the SEC filing. The company maintains strong liquidity with a current ratio of 4.87 and operates with moderate leverage, showing a debt-to-equity ratio of 0.57.
The Form 4 filing also detailed various derivative securities held by Lampropoulos, including non-qualified stock options with varying exercise prices and expiration dates. However, no new derivative transactions were reported in this filing. InvestingPro analysis reveals 10+ additional key insights about MMSI’s valuation and financial performance, available in the comprehensive Pro Research Report.
In other recent news, Merit Medical Systems has reported several key developments. The company announced the completion of its acquisition of Biolife Delaware L.L.C. for $120 million, a move expected to contribute $10 to $11 million in revenue in 2025 and approximately $18 million annually by 2026. This acquisition is anticipated to be accretive to Merit Medical (TASE:BLWV)’s non-GAAP gross margin and operating margin in 2025 and slightly accretive to non-GAAP net income and earnings per share in 2026. Merit Medical also released positive results from its WAVE trial for the WRAPSODY CIE device, with superior performance in maintaining primary patency compared to traditional methods. Additionally, Health Canada approved the WRAPSODY CIE, allowing for its commercialization in Canada. In terms of analyst activity, Canaccord Genuity raised its price target for Merit Medical to $112, maintaining a Buy rating, while Needham adjusted its target to $100 but also retained a Buy rating. Despite tariff-related challenges affecting EPS guidance, Merit Medical’s first-quarter earnings exceeded expectations, with revenue and EPS surpassing consensus estimates. The company has maintained its full-year 2025 revenue guidance, projecting net sales between $1.480 and $1.501 billion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.